Acute Myeloid Leukemia (AML), MLL Rearrangement
Conditions
Keywords
acute myeloid leukemia, leukemia stem cell, allo-SCT
Brief summary
The goal of this observational study is to learn about the predict value of leukemia stem cell for acute myeloid leukemia patients with MLL-rearrangement. The main question it aims to answer is: • Could be leukemia stem cell used for relapse prediction in acute myeloid leukemia patients with MLL-rearrangement? Leukemia stem cell will be detected at the same time for participants who detected minimal residual disease using bone marrow as part of their regular medical care to answer the question.
Interventions
DIAGNOSTIC_TESTDetection of leukemia stem cell using multiparameter flow cytometry
For AML patients with MLL rearrangement enrolled, leukemia stem cell will be detcted at diagnosis and during follow-up. A traditional Minimal residual disease was deteced as normal medical care, simultaneously, leukemia stem cell will be detcted using the sample bone marrow sample.
Sponsors
Peking University People's Hospital
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
6 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
Acute myeloiud leukemia patients with MLL arrangement aging 6-60 years recieving chemoterapy or allo-geneic hematopoietic stem cell transplantation.
Exclusion criteria
1. Patients who cannot recieve chemoterapy or allo-geneic hematopoietic stem cell transplantation. 2. Patients who cannot comply with the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Relapse | Immediately after chemotheray or allo-SCT, through study completion, median follow-up on an average of 1 year. | Relapse was defined by the morphological evidence of disease in the peripheral blood, BM or extramedullary sites |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| leukemia-free survival | Immediately after chemotheray or allo-SCT, through study completion, median follow-up on an average of 1 year. | Leukemia-free survival was defined as survival in continuous complete remission. |
| overall survival | Immediately after chemotheray or allo-SCT, through study completion, median follow-up on an average of 1 year. | Overall survival referred to patients who survived until the final follow-up time point |
Countries
China
Contacts
CONTACTSiqi Li, PhD
Outcome results
None listed